凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海医药2007年第三季度报告

公告日期 2007-10-27
股票简称:上海医药 股票代码:601607
股票代码:600849 股票简称:上海医药

上海市医药股份有限公司2007年第三季度报告

    1重要提示
    1.1本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    1.2公司董事长钱◇先生、董平先生,独立董事王巍先生、冯正权先生因故未出席董事会会议,分别委托董事徐国雄先生、胡逢祥先生、独立董事李志强先生代为表决。1.3公司第三季度财务报告未经审计。
    1.4公司董事长钱◇,总经理余金琦及财务副总监许薇薇声明:保证本季度报告中财务报告的真实、完整。
    2公司基本情况简介
    2.1主要会计数据及财务指标
                                                                                     币种:人民币
                                                                                 本报告期末比上
                                              本报告期末         上年度期末       年度期末增减
                                                                                        (%)
     总资产(元)                            7,354,334,894.00   6,692,759,758.07             9.88
     股东权益(不含少数股东权益)(元)         1,635,531,867.05   1,574,707,304.71            3.86
     每股净资产(元)                                     3.51               4.05          -13.38
                                                    年初至报告期期末             比上年同期增减
                                                        (1-9月)                      (%)
     经营活动产生的现金流量净额(元)                              291,899,828.46          256.77
     每股经营活动产生的现金流量净额(元)                                    0.51          197.31
                                                报告期         年初至报告期期末  本报告期比上年
                                              (7-9月)          (1-9月)         同期增减(%)
     净利润(元)                                30,012,748.07      85,852,964.60           21.83
     基本每股收益(元)                                   0.05               0.15            1.53
     扣除非经常性损益后基本每股收益(元)            -                       0.14         -
     稀释每股收益(元)                                   0.05               0.15            1.53
                                                                                  增加0.35个百
     净资产收益率(%)                                    1.50               4.30
                                                                                 分点
     扣除非经常性损益后的净资产收益率                                             增加0.46个百
                                                        1.45               4.12
      (%)                                                                        分点
                                                                        年初至报告期期末金额
                           非经常性损益项目                                  (1-9月)
                                                                               (元)
     非流动资产处置损益                                                            2,132,534.70
     计入当期损益的政府补助,但与公司业务密切相关,按照国家统一
                                                                                   1,896,891.88
     标准定额或定量享受的政府补助除外
     除上述各项之外的其他营业外收支净额                                             -513,937.63
     合计                                                                          3,515,488.95
        注:与上年同比,净利润与每股收益增长率不一致、每股净资产减少的原因是公司于2007年8月实施了每10股公积金转增2股的2006年度资本公积金转增股本方案,本报告期每股数据按摊薄后的新总股本569,172,884股计算;上年同期每股数据按转增前的原总股本474,310,737股计算。
        2.2报告期末股东总人数及前十名无限售条件流通股股东持股表
                                                                                        单位:股
     报告期末股东总数(户)                                                              61,372
                                前十名无限售条件流通股股东持股情况
                                       期末持有无限售条
             股东名称(全称)                                                种类
                                        件流通股的数量
     中国工商银行-华安中小盘成长
                                              26,674,562                           人民币普通股
     股票型证券投资基金
     中国工商银行-鹏华优质治理股
                                              11,680,399                           人民币普通股
     票型证券投资基金(LOF)
     中国农业银行-中邮核心优选股
                                               9,651,201                           人民币普通股
     票型证券投资基金
     中国农业银行-大成创新成长混
                                               8,464,433                           人民币普通股
     合型证券投资基金
     全国社保基金一零二组合                    4,800,000                           人民币普通股
     兴业银行股份有限公司-万家和
                                               4,771,400                           人民币普通股
     谐增长混合型证券投资基金
     中国太平洋人寿保险股份有限公
                                               4,519,242                           人民币普通股
     司-分红-个人分红
     中国建设银行-鹏华价值优势股
                                               4,040,662                           人民币普通股
     票型证券投资基金
     中国工商银行-国投瑞银瑞福分
                                               3,839,900                           人民币普通股
     级股票型证券投资基金
     北京奥通达投资咨询有限公司                3,558,060                           人民币普通股
        3重要事项
        3.1公司主要会计报表项目、财务指标大幅度变动的情况及原因
        √适用□不适用
        1、截至报告期末,资产负债表项目大幅度变动的情况及原因:
      项目      2007年9月末           2007年初        变动比例             变动原因
    货币资金     714,818,467.32     534,755,148.77      33.67% 月末资金集中回笼影响
    应收账款   2,388,553,510.99    1,835,825,992.16     30.11% 商品销售规模扩大
    应付票据     549,037,291.06      317,135,887.23     73.12% 应付票据使用量增加
                                                                商品销售规模扩大;引进新的供
    应付账款   2,238,652,267.67    1,797,318,250.25     24.56%
                                                                应商和品种
        2、报告期内,利润表项目大幅度变动的情况及原因:
      项目       2007年1-9月         2006年1-9月         变动比例             变动原因
                                                                      采购折让方式变化;商品销售
     毛利额        743,082,721.05        607,716,519.51       22.27% 增长
                                                                      采购折让成本化;预提市场开
    销售费用       346,624,457.43        259,657,551.34       33.49%
                                                                      发费
                                                                      利率上升影响;物流项目完工
    财务费用        96,148,065.37         79,487,823.11       20.96% 利息费用化;采购折让方式变
                                                                      化,造成核算变化
        3、报告期内,现金流量表表项目大幅度变动的情况及原因:
            项目           2007年1-9月        2006年1-9月       变动比例           变动原因
                                                                               通过应付账款和应付票
                                                                               据的精细化管理,加快现
     经营活动产生的现金
                             291,899,828.46       81,818,220.72    256.77%    金周转天数,增加经营性
          流量净额
                                                                               现金流量
        3.2重大事项进展情况及其影响和解决方案的分析说明
        □适用√不适用
        3.3公司、股东及实际控制人承诺事项履行情况
        √适用□不适用
        原非流通股东在股权分置改革过程中做出的承诺事项及其履行情况
       股东名称                            承诺事项                           承诺履行情况    备注
                   ①自股权分置改革方案实施之日起,上海医药(集团)有限
                   公司所持原非流通股股份在二十四个月内不上市交易或者转
     上海医药
                   让;②在前项规定期满后,上海医药(集团)有限公司通过
     (集团)有                                                              正在履行承诺
                   证券交易所挂牌交易出售原非流通股股份,出售数量占公司
     限公司
                   股份总数的比例在十二个月内不超过百分之五,在二十四个
                   月内不超过百分之十。
        3.4预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
        □适用√不适用
        3.5其他需要说明的重大事项
        3.5.1公司持有其他上市公司股权情况
        √适用□不适用
                                                占该公
      序   股票代                  持股数量                初始投资成本
                        简称                    司股权                          会计核算科目
      号     码                      (股)                     (元)
                                               比例(%)
     1     HK8231   复旦张江      139,586,000    19.66%     19,147,723.08   长期股权投资
     2     601988   中国银行        1,600,000       <1%      8,051,200.00   可供出售金融资产
     3     601398   工商银行          600,000       <1%      3,775,800.00   可供出售金融资产
     4     600018   上港集团          480,000       <1%       3,509,760.00  可供出售金融资产
     5     600001   邯郸钢铁          180,000       <1%       1,621,440.00  可供出售金融资产
     6     000903   云内动力          145,000       <1%       2,765,730.00  可供出售金融资产
     7     600602   广电电子          100,000       <1%         934,500.00  可供出售金融资产
     8     000935   四川双马           80,000       <1%       1,256,560.00  可供出售金融资产
     9     600592   龙溪股份           80,000       <1%       1,600,080.00  可供出售金融资产
     10    601919   建设银行           76,000       <1%        490,200.00   可供出售金融资产
     11    600576   万好万家           57,724       <1%        646,624.25   可供出售金融资产
     12    000911   南宁糖业           50,000       <1%        693,850.00   可供出售金融资产
     13    600479   千金药业           20,000       <1%        698,080.00   可供出售金融资产
     14    601088   中国神华           12,000       <1%        443,880.00   可供出售金融资产
     15    600276   恒瑞医药           10,000       <1%         398,780.00  可供出售金融资产
     16    600716   ST耀华             10,000       <1%         100,390.00  可供出售金融资产
     17    601169   北京银行           10,000       <1%         125,000.00  可供出售金融资产
     18    601588   北辰实业           10,000       <1%         137,890.00  可供出售金融资产
     19    000002   万科A              10,000       <1%         321,340.00  可供出售金融资产
     20    000619   海螺型材           10,000       <1%         125,530.00  可供出售金融资产
     21    002032   苏泊尔             10,000       <1%        386,620.00   可供出售金融资产
                                  288,504.00                    288,504.00
     22    601328   交通银行                        <1%                     可供出售金融资产
                                  (限售)                        (限售)
                                  65,450                            65,450
     23    600631   百联股份                        <1%                     可供出售金融资产
                                  (限售)                       (限售)
     合计                             --          --        47,896,001.33            --
        3.5.2公司持有非上市金融企业、拟上市公司股权的情况
        √适用□不适用
                                   初始投资金                                       期末账面价
                                                  持股数量      占该公司股权比例
            持有对象名称               额                                               值
                                                     (股)             (%)
                                     (元)                                           (元)
      上海申银万国证券股份有限
                                    20,000,000    20,000,000                  <1%    20,000,000
                           公司
      中国银河证券股份有限公司      50,000,000    10,000,000                  <1%    50,000,000
                小计                70,000,000    30,000,000           -            70,000,000
                                                                         上海市医药股份有限公司
                                                                               法定代表人:钱◇
                                                                               2007年10月27日
     4附录
                                           合并资产负债表
                                         2007年09月30日
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
                 项目                         期末余额                       年初余额
     流动资产:
     货币资金                                     714,818,467.32                 534,755,148.77
     结算备付金
     拆出资金
     交易性金融资产
     应收票据                                      67,225,900.81                  56,154,513.02
     应收账款                                   2,388,553,510.99               1,835,825,992.16
     预付款项                                      98,800,951.92                 252,767,464.38
     应收保费
     应收分保账款
     应收分保合同准备金
     应收利息
     应收股利                                       1,066,375.32                   1,242,805.32
     其他应收款                                   489,302,369.15                 481,335,693.54
     买入返售金融资产
     存货                                       1,201,803,155.64               1,223,088,393.90
     一年内到期的非流动资产
     其他流动资产
     流动资产合计                               4,961,570,731.15               4,385,170,011.09
     非流动资产:
     发放贷款及垫款
     可供出售金融资产                              30,771,444.25                  20,154,220.00
     持有至到期投资
     长期应收款                                    50,000,000.00                  50,000,000.00
     长期股权投资                                 577,772,246.06                 560,206,685.16
     投资性房地产
     固定资产                                   1,237,849,223.67               1,183,645,869.97
     在建工程                                      78,886,125.53                  65,285,135.09
     工程物资
     固定资产清理                                     -59,022.07
     生产性生物资产
     油气资产
     无形资产                                     379,637,715.73                 384,810,454.31
     开发支出
     商誉
     长期待摊费用                                  10,746,832.24                  16,327,785.01
     递延所得税资产                                27,159,597.44                  27,159,597.44
     其他非流动资产
     非流动资产合计                             2,392,764,162.85               2,307,589,746.98
     资产总计                                   7,354,334,894.00               6,692,759,758.07
     流动负债:
     短期借款                                   2,045,210,000.00               2,159,700,000.00
     向中央银行借款
     吸收存款及同业存放
     拆入资金
     交易性金融负债
     应付票据                                     549,037,291.06                 317,135,887.23
     应付账款                                   2,238,652,267.67               1,797,318,250.25
     预收款项                                      66,771,955.24                 158,519,077.69
     卖出回购金融资产款
     应付手续费及佣金
     应付职工薪酬                                  40,551,362.82                  27,656,151.61
     应交税费                                      21,231,401.23                  19,469,407.35
     应付利息                                       6,181,610.17                   6,110,812.27
     应付股利                                      14,994,648.19                   7,151,358.52
     其他应付款                                   336,042,165.16                 202,382,534.64
     应付分保账款
     保险合同准备金
     代理买卖证券款
     代理承销证券款
     一年内到期的非流动负债                                                           73,174.98
     其他流动负债
     流动负债合计                               5,318,672,701.54               4,695,516,654.54
     非流动负债:
     长期借款                                       1,240,000.00                   1,240,000.00
     应付债券
     长期应付款                                    31,044,610.14                  24,671,335.84
     专项应付款
     预计负债                                       4,093,656.69                  46,061,014.23
     递延所得税负债                                 1,170,377.85                   2,913,114.45
     其他非流动负债                                                                   44,328.13
     非流动负债合计                                37,548,644.68                  74,929,792.65
     负债合计                                   5,356,221,346.22               4,770,446,447.19
     所有者权益(或股东权益):
     实收资本(或股本)                           569,172,884.00                 474,310,737.00
     资本公积                                     591,830,713.25                 686,787,722.40
     减:库存股
     盈余公积                                     328,837,178.31                 328,837,178.31
     一般风险准备
     未分配利润                                   145,691,091.49                  84,771,667.00
     外币报表折算差额
     归属于母公司所有者权益合计                 1,635,531,867.05               1,574,707,304.71
     少数股东权益                                 362,581,680.73                 347,606,006.17
     所有者权益合计                             1,998,113,547.78               1,922,313,310.88
     负债和所有者权益总计                       7,354,334,894.00               6,692,759,758.07
    公司法定代表人:钱◇      主管会计工作负责人:余金琦     会计机构负责人:许薇薇
                                          母公司资产负债表
                                         2007年09月30日
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
                 项目                         期末余额                       年初余额
     流动资产:
     货币资金                                     321,046,011.01                 152,333,108.39
     交易性金融资产
     应收票据                                      23,162,778.71                  29,338,299.40
     应收账款                                   1,174,536,827.22                 865,676,291.22
     预付款项                                      76,292,927.28                 153,612,852.20
     应收利息
     应收股利
     其他应收款                                   873,433,137.53                 808,024,782.19
     存货                                         617,974,569.88                 669,688,586.33
     一年内到期的非流动资产
     其他流动资产
     流动资产合计                               3,086,446,251.63               2,678,673,919.73
     非流动资产:
     可供出售金融资产
     持有至到期投资
     长期应收款
     长期股权投资                               1,336,805,688.27               1,360,722,680.43
     投资性房地产
     固定资产                                     710,178,866.16                 697,020,004.56
     在建工程                                       2,069,458.00                   1,172,498.00
     工程物资
     固定资产清理
     生产性生物资产
     油气资产
     无形资产                                      64,190,306.83                  65,333,816.96
     开发支出
     商誉
     长期待摊费用                                     280,082.59                   1,261,677.25
     递延所得税资产                                19,585,079.61                  19,585,079.61
     其他非流动资产
     非流动资产合计                             2,133,109,481.46               2,145,095,756.81
     资产总计                                   5,219,555,733.09               4,823,769,676.54
     流动负债:
     短期借款                                   1,792,000,000.00               1,956,000,000.00
     交易性金融负债
     应付票据                                     530,112,959.03                 311,711,443.72
     应付账款                                     987,286,427.21                 741,525,896.94
     预收款项                                      25,258,168.30                 107,886,067.39
     应付职工薪酬                                   2,090,325.11                     975,603.43
     应交税费                                       6,115,058.82                  11,324,327.48
     应付利息                                       2,936,657.00                   3,268,099.08
     应付股利
     其他应付款                                   220,860,533.97                  38,684,638.38
     一年内到期的非流动负债
     其他流动负债
     流动负债合计                               3,566,660,129.44               3,171,376,076.42
     非流动负债:
     长期借款
     应付债券
     长期应付款                                    24,031,413.74                  17,623,857.04
     专项应付款
     预计负债                                                                     25,230,000.00
     递延所得税负债
     其他非流动负债
     非流动负债合计                                24,031,413.74                  42,853,857.04
     负债合计                                   3,590,691,543.18               3,214,229,933.46
     所有者权益(或股东权益):
     实收资本(或股本)                           569,172,884.00                 474,310,737.00
     资本公积                                     595,389,941.44                 686,787,722.40
     减:库存股
     盈余公积                                     232,750,929.26                 232,750,929.26
     未分配利润                                   231,550,435.21                 215,690,354.42
     所有者权益(或股东权益)合
                                                1,628,864,189.91               1,609,539,743.08
     计
     负债和所有者权益(或股东权
                                                5,219,555,733.09               4,823,769,676.54
     益)总计
    公司法定代表人:钱◇      主管会计工作负责人:余金琦     会计机构负责人:许薇薇
                                             合并利润表
                                           2007年1-9月
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
               本期金额(7-9      上期金额(7-9      年初至报告期期末金    上年年初至报告期期末
      项目
                    月)               月)             额(1-9月)           金额(1-9月)
     一、营
     业总收   3,382,123,991.92   2,886,068,269.52       9,697,987,046.79       8,623,285,145.93
     入
     其中:
     营业收
     入
     利息收
     入
     已赚保
     费
     手续费
     及佣金
     收入
     二、营
     业总成   3,142,314,297.18   2,682,865,079.98      8,954,904,325.74        8,015,568,626.42
     本
     其中:
     营业成
     本
     利息支
     出
     手续费
     及佣金
     支出
     退保金
     赔付支
     出净额
     提取保
     险合同
     准备金
     净额
     保单红
     利支出
     分保费
     用
     营业税
     金及附       4,755,423.06       3,887,756.60          14,235,958.75           8,629,612.04
     加
     销售费     112,811,334.26      97,956,669.21         346,624,457.43         259,657,551.34
     用
     管理费
                 64,516,446.11      46,062,046.03         200,014,549.08         172,379,304.56
     用
     财务费
                 27,493,978.90      32,146,362.02          96,148,065.37          79,487,823.11
     用
     资产减
                 -2,404,417.51                             -2,598,776.60
     值损失
     加:公
     允价值
     变动收
     益(损
     失以
     “-”
     号填
     列)
     投资收
     益(损
     失以
                  6,821,302.80       4,496,409.36          19,973,608.40          19,159,736.22
     “-”
     号填
     列)
     其中:
     对联营
     企业和
     合营企
     业的投
     资收益
     汇兑收
     益(损
     失以
     “-”
     号填
     列)
     三、营
     业利润
     (亏损
     以          39,458,232.72      27,646,765.04         108,632,075.42         106,721,964.68
     “-”
     号填
     列)
     加:营
     业外收       2,160,582.38       8,152,177.57           7,776,791.69          11,981,583.44
     入
     减:营
     业外支       1,867,057.48       1,499,167.01           3,831,726.14           5,327,467.78
     出
     其中:
     非流动
     资产处
     置净损
     失
     四、利
     润总额
     (亏损
     总额以      39,751,757.62      34,299,775.60         112,577,140.97         113,376,080.34
     “-”
     号填
     列)
     减:所
     得税费       9,739,009.55       9,665,282.20          26,724,176.37          26,879,988.29
     用
     五、净
     利润
     (净亏
     损以        30,012,748.07      24,634,493.40          85,852,964.60          86,496,092.04
     “-”
     号填
     列)
     归属于
     母公司
     所有者
                 21,145,929.79      17,529,626.01          60,919,424.49          68,626,660.16
     的净利
     润
     少数股
     东损益       8,866,818.28       7,104,867.39          24,933,540.11          17,869,431.88
     六、每
     股收
     益:
     (一)
     基本每               0.05                                      0.15
     股收益
     (二)
     稀释每               0.05                                      0.15
     股收益
    公司法定代表人:钱◇      主管会计工作负责人:余金琦     会计机构负责人:许薇薇
                                            母公司利润表
                                           2007年1-9月
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
                    本期金额(7-9      上期金额(7-9     年初至报告期期末    上年年初至报告期期
        项目
                        月)               月)           金额(1-9月)       末金额(1-9月)
     一、营业收
                  1,856,953,559.60   1,594,174,169.90     5,305,264,371.57     4,665,155,874.45
     入
     减:营业成
                  1,762,432,800.04   1,518,664,387.92     5,000,281,917.32     4,438,409,643.31
     本
     营业税金及
                      1,549,937.46       1,918,888.00         5,142,560.06         1,777,333.35
     附加
     销售费用        58,994,439.44       39,887,758.43      174,080,000.01        97,680,047.63
     管理费用         6,625,281.71        5,502,708.36       37,649,237.69        31,275,630.81
     财务费用        21,517,558.64       23,348,487.88       78,465,981.51        59,627,835.21
     资产减值损
                     -2,878,524.55                           -2,878,524.55
     失
     加:公允价
     值变动收益
     (损失以
     “-”号填
     列)
     投资收益
     (损失以
                      2,717,875.49                            3,193,028.76           815,712.33
     “-”号填
     列)
     其中:对联
     营企业和合
     营企业的投
     资收益
     二、营业利
     润(亏损以
                     11,429,942.35       4,851,939.31        15,716,228.29        37,201,096.47
     “-”号填
     列)
     加:营业外
                      1,375,966.80        2,773,753.32        2,229,645.28         2,881,322.45
     收入
     减:营业外
                        141,334.84          160,085.51          216,644.77         2,252,117.03
     支出
     其中:非流
     动资产处置
     损失
     三、利润总
     额(亏损总
                     12,664,574.31       7,465,607.12        17,729,228.80        37,830,301.89
     额以“-”
     号填列)
     减:所得税
                      1,549,043.31       1,905,881.51         1,869,148.01          6,740,624.19
     费用
     四、净利润
     (净亏损以
                    11,115,531.00        5,559,725.61        15,860,080.79        31,089,677.70
     “-”号填
     列)
    公司法定代表人:钱◇            主管会计工作负责人:余金琦             会计机构负责人:许薇薇
                                           合并现金流量表
                                           2007年1-9月
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
                                                                          上年年初至报告期期末
                                                年初至报告期期末金额
                       项目                                                       金额
                                                      (1-9月)
                                                                               (1-9月)
     一、经营活动产生的现金流量:
     销售商品、提供劳务收到的现金                    11,974,665,715.74        10,185,512,504.57
     客户存款和同业存放款项净增加额
     向中央银行借款净增加额
     向其他金融机构拆入资金净增加额
     收到原保险合同保费取得的现金
     收到再保险业务现金净额
     保户储金及投资款净增加额
     处置交易性金融资产净增加额
     收取利息、手续费及佣金的现金
     拆入资金净增加额
     回购业务资金净增加额
     收到的税费返还                                      65,570,494.16            14,776,670.98
     收到其他与经营活动有关的现金                           413,027.66            16,175,122.39
     经营活动现金流入小计                            12,040,649,237.56        10,216,464,297.94
     购买商品、接受劳务支付的现金                    11,130,995,828.40         9,439,003,784.62
     客户贷款及垫款净增加额
     存放中央银行和同业款项净增加额
     支付原保险合同赔付款项的现金
     支付利息、手续费及佣金的现金
     支付保单红利的现金
     支付给职工以及为职工支付的现金                     226,477,944.54           250,495,348.36
     支付的各项税费                                     215,152,594.07           164,061,896.82
     支付其他与经营活动有关的现金                       176,123,042.09           281,085,047.42
     经营活动现金流出小计                            11,748,749,409.10        10,134,646,077.22
     经营活动产生的现金流量净额                         291,899,828.46            81,818,220.72
     二、投资活动产生的现金流量:
     收回投资收到的现金                                     381,233.60            85,470,531.19
     取得投资收益收到的现金                              18,374,943.87             6,419,334.76
     处置固定资产、无形资产和其他长期资产
                                                         17,289,975.82            35,926,438.51
     收回的现金净额
     处置子公司及其他营业单位收到的现金净
     额
     收到其他与投资活动有关的现金                             8,370.41
     投资活动现金流入小计                                36,054,523.70           127,816,304.46
     购建固定资产、无形资产和其他长期资产
                                                         50,416,609.35           113,178,728.31
     支付的现金
     投资支付的现金                                      15,526,863.81             1,729,006.18
     质押贷款净增加额
     取得子公司及其他营业单位支付的现金净
     额
     支付其他与投资活动有关的现金                            11,533.61             1,795,182.80
     投资活动现金流出小计                                65,955,006.77           116,702,917.29
     投资活动产生的现金流量净额                         -29,900,483.07            11,113,387.17
     三、筹资活动产生的现金流量:
     吸收投资收到的现金
     其中:子公司吸收少数股东投资收到的现
     金
     取得借款收到的现金                                                          157,417,590.22
     发行债券收到的现金
     收到其他与筹资活动有关的现金                       121,579,694.43
     筹资活动现金流入小计                               121,579,694.43           157,417,590.22
     偿还债务支付的现金                                 114,490,000.00
     分配股利、利润或偿付利息支付的现金                  86,378,384.91            84,734,137.84
     其中:子公司支付给少数股东的股利、利
     润
     支付其他与筹资活动有关的现金                         8,901,942.06             5,329,635.66
     筹资活动现金流出小计                               209,770,326.97            90,063,773.50
     筹资活动产生的现金流量净额                         -88,190,632.54            67,353,816.72
     四、汇率变动对现金及现金等价物的影响                 6,254,605.70
     五、现金及现金等价物净增加额                       180,063,318.55           160,285,424.61
     加:期初现金及现金等价物余额                       534,755,148.77           314,205,621.01
     六、期末现金及现金等价物余额                       714,818,467.32           474,491,045.62
    公司法定代表人:钱◇     主管会计工作负责人:余金琦     会计机构负责人:许薇薇
                                          母公司现金流量表
                                           2007年1-9月
    编制单位:上海市医药股份有限公司
                                                         单位:元币种:人民币审计类型:未经审计
                                                                          上年年初至报告期期末
                                                年初至报告期期末金额
                       项目                                                       金额
                                                      (1-9月)
                                                                               (1-9月)
     一、经营活动产生的现金流量:
     销售商品、提供劳务收到的现金                     5,917,062,779.88          4,962,025,192.62
     收到的税费返还                                      60,241,978.70             12,646,810.96
     收到其他与经营活动有关的现金                                    -             13,397,838.13
     经营活动现金流入小计                             5,977,304,758.58          4,988,069,841.71
     购买商品、接受劳务支付的现金                     5,570,935,791.42          4,824,804,682.94
     支付给职工以及为职工支付的现金                      95,840,826.24            94,864,360.87
     支付的各项税费                                      72,209,101.29            50,788,671.71
     支付其他与经营活动有关的现金                       -37,665,987.54            87,549,526.40
     经营活动现金流出小计                             5,701,319,731.41         5,058,007,241.92
     经营活动产生的现金流量净额                         275,985,027.17           -69,937,400.21
     二、投资活动产生的现金流量:
     收回投资收到的现金                                                            68,096,991.19
     取得投资收益收到的现金                              34,869,249.11             23,571,510.22
     处置固定资产、无形资产和其他长期资产
                                                            168,607.84            35,604,800.00
     收回的现金净额
     处置子公司及其他营业单位收到的现金净
                                                         34,460,000.00
     额
     收到其他与投资活动有关的现金
     投资活动现金流入小计                                69,497,856.95           127,273,301.41
     购建固定资产、无形资产和其他长期资产
                                                          9,943,805.36             95,524,968.62
     支付的现金
     投资支付的现金                                      34,460,000.00
     取得子公司及其他营业单位支付的现金净
     额
     支付其他与投资活动有关的现金
     投资活动现金流出小计                                44,403,805.36             95,524,968.62
     投资活动产生的现金流量净额                          25,094,051.59             31,748,332.79
     三、筹资活动产生的现金流量:
     吸收投资收到的现金
     取得借款收到的现金                                                           180,000,000.00
     收到其他与筹资活动有关的现金                       100,000,000.00                         -
     筹资活动现金流入小计                               100,000,000.00            180,000,000.00
     偿还债务支付的现金                                 164,000,000.00                         -
     分配股利、利润或偿付利息支付的现金                  61,605,286.23             76,703,500.31
     支付其他与筹资活动有关的现金                         6,760,889.91                         -
     筹资活动现金流出小计                               232,366,176.14             76,703,500.31
     筹资活动产生的现金流量净额                        -132,366,176.14            103,296,499.69
     四、汇率变动对现金及现金等价物的影响
     五、现金及现金等价物净增加额                       168,712,902.62             65,107,432.27
     加:期初现金及现金等价物余额                       152,333,108.39             68,278,196.15
     六、期末现金及现金等价物余额                       321,046,011.01            133,385,628.42
        公司法定代表人:钱◇     主管会计工作负责人:余金琦     会计机构负责人:许薇薇
数据加载中...
prevnext
手机查看股票